Biomx Inc SEC Filings

BiomX Inc. (PHGE) amended its Form S-3 prospectus to update the amount it may sell under an existing at-the-market (ATM) agreement with H.C. Wainwright. The company currently may offer and sell up to $1,765,939 of common stock under General Instruction I.B.6 of Form S-3, excluding approximately $20,734 already sold under the prior prospectus. The aggregate market value of shares held by non-affiliates used in the calculation is $15,441,621, based on 23,756,340 non-affiliate shares at $0.65 per share. BiomX has sold $3,381,268 under the same instruction during the prior 12-month period. Common stock trades on the NYSE American under PHGE; the last reported sale price was $0.56.

BiomX Inc. (PHGE) reported continuing clinical progress alongside notable financing activity but disclosed material financing pressure. The company held $15.19 million in total cash and restricted cash at June 30, 2025 (amounts presented in USD in thousands) and recorded a net loss of $13.7 million for the six months ended June 30, 2025. Operating cash used was $14.82 million for the six-month period, and accumulated deficit totaled $194.39 million, raising substantial doubt about the company’s ability to continue as a going concern.

On the clinical front, BiomX reported positive Phase 2 results for BX211 in diabetic foot osteomyelitis with a statistically significant percent area reduction of ulcers (p = 0.046 at week 12) and other favorable secondary trends. BX004 (CF) advanced into a randomized Phase 2b with first patient dosed July 14, 2025, and holds FDA Fast Track and Orphan Drug designations. The company completed equity and warrant financings in 2024–2025 and recorded gross proceeds from the February 2025 SPA of $5,527 and related financings and warrant exercises that provided cash in the period, but management states current funds are not sufficient to fund operations for at least one year without additional financing.

BiomX Inc. furnished an 8-K reporting that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The filing does not include the underlying financial statements or numeric results; instead, the press release itself is furnished as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104.

The submission is a disclosure furnishing rather than a full presentation of results within the 8-K text. The report is signed on behalf of the company by Chief Executive Officer Jonathan Solomon.

Morgan Stanley and subsidiary Morgan Stanley & Co. LLC filed a Schedule 13G (event date 06/30/25, signed 08/05/25) disclosing passive ownership of 1,854,032 BiomX Inc. (PHGE) common shares (CUSIP 09090D301). The position equals 7.1 % of the outstanding class, crossing the 5 % reporting threshold. Both filers report 0 sole voting/dispositive power and shared voting & dispositive power over all shares, indicating the stake is managed collectively across Morgan Stanley reporting units. The filing is made under Rule 13d-1(b) as a qualified institutional investor; Morgan Stanley is classified as HC, CO and the broker-dealer unit as BD, CO.

The certification states the shares were acquired in the ordinary course and not to influence control. No transactions, price data, or strategic intent beyond passive ownership are provided. Nonetheless, disclosure of a large institutional holder may improve liquidity and signal market confidence in BiomX’s prospects.

BiomX Inc. (NYSE American: PHGE) filed a Form 8-K to disclose administrative details for its 2025 Annual Meeting of Stockholders.

• Meeting date: Thursday, October 16, 2025
• Record date: Close of business August 22, 2025
• Shareholder proposal deadline: 5:00 p.m. ET, August 15, 2025 (per Rule 14a-8)

The disclosure is required because the meeting date moves more than 30 days from last year’s meeting, resetting SEC and bylaw timelines. No financial results, transactions, or leadership changes were reported.

OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP L.P., Carl L. Gordon and Erez Chimovits filed Amendment No. 6 to their Schedule 13D on BiomX Inc. (ticker PHGE). The amendment is an exit filing that discloses the group has fallen below the 5% ownership threshold.

Key details:

• On 18 June 2025, OrbiMed Israel Partners ("OIP") sold 1,787,767 common shares of BiomX at $0.34 per share.
• After the sale, the group’s beneficial holdings consist solely of 276,150 shares (all issuable upon conversion of 223 Series X Non-Voting Convertible Preferred Stock and 2,538,500 warrants).
• This position represents 1.0% of BiomX’s 26.45 million shares outstanding (including the shares underlying the preferred stock and warrants).
• The filing emphasises that, as of 18 June 2025, the reporting persons are no longer beneficial owners of more than 5% of BiomX’s outstanding shares.
• The investment committee comprising Gordon and Chimovits continues to review the position and may buy or sell additional shares based on market conditions, but no specific future plans were disclosed.

Implications: The disposal of nearly 1.8 million shares by a long-standing institutional holder removes a significant block from the shareholder register and may affect market perception of insider confidence. However, the remaining warrants and preferred shares ensure the group still retains some exposure to BiomX’s future performance.